Back to Library
Muscle GrowthHormone Optimization

CJC-1295 No DAC

Short-acting GHRH analogue for pulsatile GH research

Overview

CJC-1295 No DAC, also known as MOD-GRF 1-29, is a synthetic, short-acting analogue of human growth hormone–releasing hormone (GHRH 1-29). It acts as a selective GHRH receptor agonist to stimulate pulsatile Growth Hormone (GH) release. Supplied as a lyophilized peptide for research use only.

Chemical Information

IUPAC Name
Modified Growth Hormone Releasing Factor 1-29
Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Molecular Mass
3367.9 Da
Formula
C152H252N44O42
CJC-1295 No DAC Chemical Structure

Mechanism of Action

Functions as a selective Growth Hormone-Releasing Hormone (GHRH) receptor agonist that mimics the biological activity of endogenous GHRH (1-29). By binding to GHRH receptors on the anterior pituitary’s somatotroph cells, it activates the cAMP-dependent signaling pathway (G-protein coupled receptor Gs → Adenylyl Cyclase → cAMP → PKA). This cascade leads to the depolarization of somatotrophs and the influx of calcium ions, triggering the exocytosis of Growth Hormone (GH) vesicles. Unlike continuous stimulation, MOD-GRF 1-29 induces a pulsatile release of GH, which preserves the body’s natural ultradian rhythm and prevents the receptor downregulation (tachyphylaxis) often seen with long-acting non-pulsatile agents. Furthermore, it is designed with four specific amino acid substitutions (Ala²→D-Ala, Gln⁸, Ala¹⁵, Leu²⁷) that protect it from rapid degradation by the DPP-IV enzyme, extending its half-life to ~30 minutes (vs. <5 mins for native GHRH) while maintaining high receptor affinity.

Potential Research Fields

Muscle growthFat metabolismSleep researchAnti-agingEndocrine modulation

Recent Research

Current research (2024–2025) emphasizes the utility of MOD-GRF 1-29 as a precision tool for 'physiological restoration' of the GH/IGF-1 axis, particularly in the context of metabolic health and longevity. Studies are increasingly focusing on its synergistic application with Ghrelin mimetics (like Ipamorelin). The 'dual-pathway' stimulation—activating the GHRH receptor (via MOD-GRF) and the Ghrelin receptor (via Ipamorelin) simultaneously—has been shown in preclinical models to produce a GH pulse significantly larger than the sum of individual administrations, without raising cortisol or prolactin. New metabolic research highlights its role in visceral adiposity. By amplifying pulsatile GH, it enhances lipolysis (fat breakdown) and protein synthesis mechanisms without the insulin resistance associated with continuous GH elevation. Additionally, sleep research is exploring its ability to deepen Slow-Wave Sleep (SWS), correlating improved nocturnal GH pulses with better neuro-recovery and cognitive maintenance in aging models.

Bibliography / Scientific References

Related Peptides

Research
Follistatin (FST)

Potent myostatin inhibitor for muscle hypertrophy

Research
IGF-1 LR3

Long-acting IGF-1 analogue for sustained anabolic activity

Peptide Information Guide
Administration Type
Injectable (Subcutaneous)

Injectable administration protocol for research.

Vial Strength
10mg
Reconstitution
Reconstitute with 2ml bacteriostatic water
Dosage Options
250 mcg
1x daily
Standard maintenance dose in research
500 mcg
1x daily
Acute protocol dose in research
Schedule
1x daily
Timing: One specific day.
Duration
3 Months
Potential Side Effects
Flushing/Warmth
mildcommon (post-injection)
Injection site reaction
lowoccasional
Research Use Only

This information is for research purposes only. Always consult with a healthcare professional before starting any peptide protocol. Individual responses may vary, and proper medical supervision is recommended for all peptide therapies.